PROTEOSTASIS THERAPEUTICS, INC. Business Operations Contracts & Agreements
14 Contracts & Agreements
- Collaboration Agreements (6 contracts)
- Development Agreements (1)
- Indemnification Agreements (2)
- Sales Agreements (2)
- Services Agreements (1)
- Settlement Agreements (1)
- Termination Agreements (1)
- Settlement Agreement and Mutual Release, dated as of April 22, 2024, by and between Kineta, Inc. and RLB Holdings, Connecticut, LLC (Filed With SEC on April 24, 2024)
- Termination Agreement by and between Yumanity Therapeutics, Inc. and MIL 40, LLC dated as of February 28, 2022 (Filed With SEC on March 4, 2022)
- Form of Director and Officer Indemnification Agreements (Filed With SEC on December 30, 2020)
- Contingent Value Rights Agreement, dated as of December 22, 2020 by and among the Company and Shareholder Representative Services LLC (Filed With SEC on December 30, 2020)
- Sales Agreement dated May 9, 2019 by and between Proteostasis Therapeutics, Inc. and H.C. Wainwright & Co., LLC (Filed With SEC on May 9, 2019)
- Amendment No. 6 to Collaboration and License Agreement dated April 23, 2018 by and between the Company and Astellas Pharma Inc (Filed With SEC on August 8, 2018)
- Sales Agreement dated March 23, 2018 by and between Proteostasis Therapeutics, Inc. and Leerink Partners LLC (Filed With SEC on March 23, 2018)
- Amendment No. 5 to Collaboration and License Agreement (Filed With SEC on August 15, 2016)
- Amendment No. 4 to Collaboration and License Agreement (Filed With SEC on May 27, 2016)
- Amendment No. 3 to Collaboration and License Agreement (Filed With SEC on December 23, 2015)
- Amendment No. 2 to Collaboration and License Agreement (Filed With SEC on December 23, 2015)
- PROTEOSTASIS THERAPEUTICS, INC. FORM OF INDEMNIFICATION AGREEMENT (Filed With SEC on December 23, 2015)
- COLLABORATION AND LICENSEAGREEMENT BETWEEN ASTELLAS PHARMA INC. AND PROTEOSTASIS THERAPEUTICS, INC. (Filed With SEC on December 23, 2015)
- RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT by and between Proteostasis Therapeutics, Inc. and Cystic FibrosisFoundation Therapeutics, Inc. Dated March 20, 2012 (Filed With SEC on December 23, 2015)
